JP2024161509A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024161509A5 JP2024161509A5 JP2024136804A JP2024136804A JP2024161509A5 JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5 JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5
- Authority
- JP
- Japan
- Prior art keywords
- multivalent antibody
- linker comprises
- hinge sequence
- antibody according
- multivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650467P | 2018-03-30 | 2018-03-30 | |
| US62/650,467 | 2018-03-30 | ||
| PCT/NL2019/050199 WO2019190327A2 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
| JP2021502692A JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Division JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024161509A JP2024161509A (ja) | 2024-11-19 |
| JP2024161509A5 true JP2024161509A5 (https=) | 2025-04-02 |
Family
ID=66349617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
| JP2024136804A Pending JP2024161509A (ja) | 2018-03-30 | 2024-08-16 | 多価抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11952424B2 (https=) |
| EP (1) | EP3774885A2 (https=) |
| JP (2) | JP7603578B2 (https=) |
| KR (1) | KR20200139189A (https=) |
| CN (1) | CN111936514A (https=) |
| AR (1) | AR115320A1 (https=) |
| AU (2) | AU2019243665B2 (https=) |
| BR (1) | BR112020019795A2 (https=) |
| CA (1) | CA3094318A1 (https=) |
| EA (1) | EA202091871A1 (https=) |
| IL (1) | IL277672A (https=) |
| MA (1) | MA52212A (https=) |
| MX (1) | MX2020010267A (https=) |
| NZ (1) | NZ767923A (https=) |
| PH (1) | PH12020551504A1 (https=) |
| SG (1) | SG11202009036YA (https=) |
| TW (1) | TW202003569A (https=) |
| WO (1) | WO2019190327A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010267A (es) | 2018-03-30 | 2020-11-06 | Merus Nv | Anticuerpo multivalente. |
| CN113227132A (zh) | 2018-12-31 | 2021-08-06 | 美勒斯公司 | 混合的结合域 |
| US20220380440A1 (en) | 2018-12-31 | 2022-12-01 | Merus N.V. | Truncated multivalent multimers |
| TW202546002A (zh) | 2019-03-29 | 2025-12-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| CN114605546A (zh) * | 2019-03-29 | 2022-06-10 | 美勒斯公司 | Cd3结合分子 |
| US20210054049A1 (en) | 2019-05-09 | 2021-02-25 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
| CN116199780A (zh) | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| CN116407626A (zh) * | 2020-01-29 | 2023-07-11 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
| JP7784039B2 (ja) * | 2020-03-31 | 2025-12-11 | 公立大学法人大阪 | 多重特異性抗体及びその製造方法 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| EP4149627A4 (en) * | 2020-05-14 | 2024-05-29 | The General Hospital Corporation | POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| MX2022014208A (es) | 2020-05-21 | 2022-12-07 | Merus Nv | Metodos y medios para la produccion de moleculas tipo ig. |
| CA3196729A1 (en) * | 2020-11-11 | 2022-05-19 | Tural AKSEL | Affinity reagents having enhanced binding and detection characteristics |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| JP2025512391A (ja) * | 2022-04-13 | 2025-04-17 | ゼンコア インコーポレイテッド | Ｐｄ－ｌ１、ｐｄ－ｌ２及び／またはｃｄ２８と結合する抗体 |
| TW202432587A (zh) | 2022-12-27 | 2024-08-16 | 荷蘭商美勒斯公司 | 產生雙特異性蛋白之方法 |
| EP4642800A1 (en) * | 2022-12-30 | 2025-11-05 | Merus N.V. | Promiscuous cd3 binding molecules |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| US20240327515A1 (en) * | 2023-03-31 | 2024-10-03 | Ibio, Inc. | Anti-cd3 antibodies |
| WO2025221674A1 (en) * | 2024-04-15 | 2025-10-23 | Eli Lilly And Company | Baffr x cd3 bispecific antibodies and methods of use |
| WO2025230409A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230410A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2026013015A1 (en) * | 2024-07-09 | 2026-01-15 | Merus N.V. | Multispecific binding moieties comprising calr and cd3 binding domains |
| WO2026018064A1 (en) | 2024-07-16 | 2026-01-22 | Merus N.V. | Multispecific multi-drug antibody-drug conjugates |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| CN101289511A (zh) * | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| JP2004523205A (ja) * | 2000-07-25 | 2004-08-05 | イムノメディクス， インコーポレイテッド | 多価標的結合タンパク質 |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PL3456190T3 (pl) | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| CA2762837C (en) | 2009-05-20 | 2021-08-03 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| TW201100543A (en) * | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| ES2542744T3 (es) | 2009-12-17 | 2015-08-11 | Novimmune Sa | Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| EP2748197A2 (en) * | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| SI2838917T1 (sl) * | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| EP3470431A1 (en) * | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| CA2896359A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| BR112016015140A2 (pt) * | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| IL301147A (en) | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
| EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| EP3204416A1 (en) | 2014-10-09 | 2017-08-16 | EngMab AG | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| SI3115376T1 (sl) * | 2015-07-10 | 2018-12-31 | Merus N.V. | Humana protitelesa, ki vežejo CD3 |
| US10683369B2 (en) | 2015-08-03 | 2020-06-16 | Engmab Sàrl | Monoclonal antibodies against BCMA |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CA3002957A1 (en) * | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| CN109476741B (zh) | 2016-03-25 | 2023-02-24 | 拜奥穆尼克斯制药 | 与cd38和pd-l1结合的分子 |
| JP2019516362A (ja) * | 2016-04-27 | 2019-06-20 | ファイザー・インク | 抗ｉｌ−３３抗体、その組成物、方法および使用 |
| CN109563166B (zh) | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| BR112019005895A2 (pt) * | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
| KR20240000650A (ko) | 2016-10-19 | 2024-01-02 | 인벤라 인코포레이티드 | 항체 구조물 |
| EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| US20200291130A1 (en) * | 2017-03-31 | 2020-09-17 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| AU2018246873B2 (en) * | 2017-03-31 | 2021-05-06 | Merus B.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
| EA202090005A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
| EA202090003A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
| EP3649155A1 (en) * | 2017-07-06 | 2020-05-13 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
| CN118580366A (zh) * | 2017-08-09 | 2024-09-03 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
| CN111432838A (zh) * | 2017-12-01 | 2020-07-17 | 美勒斯公司 | 使用双特异性抗体和il-15进行联合治疗 |
| MX2020010267A (es) | 2018-03-30 | 2020-11-06 | Merus Nv | Anticuerpo multivalente. |
| CN113227132A (zh) * | 2018-12-31 | 2021-08-06 | 美勒斯公司 | 混合的结合域 |
| US20210054049A1 (en) * | 2019-05-09 | 2021-02-25 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
| PH12022551291A1 (en) * | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| CN116407626A (zh) * | 2020-01-29 | 2023-07-11 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
-
2019
- 2019-03-29 MX MX2020010267A patent/MX2020010267A/es unknown
- 2019-03-29 TW TW108111354A patent/TW202003569A/zh unknown
- 2019-03-29 KR KR1020207030642A patent/KR20200139189A/ko not_active Ceased
- 2019-03-29 WO PCT/NL2019/050199 patent/WO2019190327A2/en not_active Ceased
- 2019-03-29 MA MA052212A patent/MA52212A/fr unknown
- 2019-03-29 JP JP2021502692A patent/JP7603578B2/ja active Active
- 2019-03-29 US US16/370,346 patent/US11952424B2/en active Active
- 2019-03-29 BR BR112020019795-5A patent/BR112020019795A2/pt unknown
- 2019-03-29 AR ARP190100836A patent/AR115320A1/es unknown
- 2019-03-29 AU AU2019243665A patent/AU2019243665B2/en active Active
- 2019-03-29 SG SG11202009036YA patent/SG11202009036YA/en unknown
- 2019-03-29 CN CN201980023259.9A patent/CN111936514A/zh active Pending
- 2019-03-29 CA CA3094318A patent/CA3094318A1/en active Pending
- 2019-03-29 EA EA202091871A patent/EA202091871A1/ru unknown
- 2019-03-29 NZ NZ767923A patent/NZ767923A/en unknown
- 2019-03-29 EP EP19721163.4A patent/EP3774885A2/en active Pending
-
2020
- 2020-09-16 PH PH12020551504A patent/PH12020551504A1/en unknown
- 2020-09-29 IL IL277672A patent/IL277672A/en unknown
-
2023
- 2023-09-01 AU AU2023222983A patent/AU2023222983A1/en active Pending
-
2024
- 2024-02-13 US US18/440,582 patent/US20240360217A1/en active Pending
- 2024-02-13 US US18/440,607 patent/US20240352127A1/en active Pending
- 2024-08-16 JP JP2024136804A patent/JP2024161509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024161509A5 (https=) | ||
| JP6753945B2 (ja) | 抗人ｐｄ−ｌ１人源化単クローン抗体及び応用 | |
| Wu et al. | Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules | |
| Schuster | Bispecific antibodies for the treatment of lymphomas: Promises and challenges | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| CN113677359A (zh) | Cd25抗体 | |
| CN109219619A (zh) | 抗lag-3抗体 | |
| AU680685B2 (en) | Retargeting antibodies | |
| JPH03500005A (ja) | 組換えｄｎａタンパクの製造方法 | |
| JP2006515503A5 (https=) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| AT503889A1 (de) | Neue multivalente immunglobuline | |
| KR960704575A (ko) | 항원-특이적 t 세포의 내성을 유도하는 방법(methods for inducing antigen-specific tcell tolerance) | |
| JP2020007318A5 (https=) | ||
| JP2024514109A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| AU2022273136A9 (en) | Binding molecule against dll3 and use thereof | |
| JPH01501201A (ja) | 抗体 | |
| TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| Silverstein | Labeled antigens and antibodies: the evolution of magic markers and magic bullets | |
| Shinde et al. | Polyvalency: an emerging trend in the development of clinical antibodies | |
| CN118702814A (zh) | 一种抗ngf单克隆抗体及其应用 | |
| Winter | Antibody engineering | |
| JP2010529950A5 (https=) |